Aradigm Receives FDA Orphan Drug Designation For Ciprofloxacin For Inhalation In Bronchiectasis
Originally posted in Cystic Fibrosis News From Medical News Today
Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ciprofloxacin for inhalation for the management of bronchiectasis (BE)…
No Comments »
RSS feed for comments on this post. TrackBack URL
by Raelene
